A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Arog Pharmaceuticals

Status and phase: Withdrawn; Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Drug: CP-868,596 + AG-013736 + docetaxel; Drug: AG-013736 + docetaxel; Drug: CP-868,596 + docetaxel; Drug: docetaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT00386555

A5301010

Details and patient eligibility

About

To determine the effectiveness of CP-868,596 + docetaxel, AG-013736 + docetaxel and CP-868,596 + AG-013736 + docetaxel in patients previously treated for non-small cell lung cancer.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Platinum-pretreated patients with advanced stage IIIb or IV NSCLC

Exclusion criteria

• Centrally-located tumors

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)